Search research articles
Contact Us
Filters
Showing results (71-80 of 115) with videos related to
Page
of 12
Sort By:
The Lancet. Oncology
|
May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2020
Reply to T.J.A. Dekker
Shanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
JCO Precision Oncology
|
December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer
Komal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2018
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2018
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update
Sharon H Giordano, Sarah Temin, Sarat Chandarlapaty, et al.
Breast Cancer Research and Treatment
|
July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
Diana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
Page
of 12
Search research articles
Search
Showing results (71-80 of 115) with videos related to
Sort By:
Page
of 12
The Lancet. Oncology
|
May 4, 2019
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura, Junji Tsurutani, Shunji Takahashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2020
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 14, 2020
Reply to T.J.A. Dekker
Shanu Modi, Haeseong Park, Rashmi K Murthy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 1, 2020
Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR<sup>+</sup>, HER2<sup>-</sup> Advanced Breast Cancer
Aditya Bardia, Shanu Modi, Mafalda Oliveira, et al.
NPJ Breast Cancer
|
March 23, 2022
Incidence of brain metastases in patients with early HER2-positive breast cancer receiving neoadjuvant chemotherapy with trastuzumab and pertuzumab
Emanuela Ferraro, Jasmeet Singh, Sujata Patil, et al.
JCO Precision Oncology
|
December 7, 2020
Measuring Tumor Epichaperome Expression Using [<sup>124</sup>I] PU-H71 Positron Emission Tomography as a Biomarker of Response for PU-H71 Plus Nab-Paclitaxel in HER2-Negative Metastatic Breast Cancer
Komal L Jhaveri, Carlos H Dos Anjos, Tony Taldone, et al.
The Oncologist
|
February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
Jasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2018
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Naren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 26, 2018
Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update
Sharon H Giordano, Sarah Temin, Sarat Chandarlapaty, et al.
Breast Cancer Research and Treatment
|
July 3, 2020
Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
Diana G Wang, Dulce M Barrios, Victoria S Blinder, et al.
Page
of 12